Treatment of severe coagulopathy in the Kasabach-Merritt syndrome with aminocaproic acid and cryoprecipitate.

The Kasabach-Merritt syndrome is characterized by thrombocytopenia associated with solitary or multiple hemangiomas.1 Coagulation studies in patients with this disease frequently reveal a profile similar to that of disseminated intravascular coagulation.2 , 3 The disorder is of particular clinical interest since complete eradication of the tumor by surgical excision or radiation eliminates the coagulopathy.4 , 5 Although the syndrome is primarily a disease of infancy, some patients survive for long periods, particularly if the coagulation defect is mild. In the absence of treatment, fatal hemorrhage can result.4 5 6 The syndrome is unique in that the coagulopathy is believed to be a manifestation of clotting and . . .

[1]  M. Weinblatt,et al.  Hemangioendothelioma with intravascular coagulation and ischemic colitis , 1984, Cancer.

[2]  R. Warrell,et al.  Intratumoral consumption of indium‐111 labeled platelets in a patient with hemangiomatosis and intravascular coagulation (Kasabach‐merritt syndrome) , 1983, Cancer.

[3]  R. Roach,et al.  Successful treatment of skeletal hemangioma and Kasabach-Merritt syndrome with aminocaproic acid. Is fibrinolysis "defensive"? , 1982, The American journal of medicine.

[4]  C. Esmon,et al.  Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. , 1981, The Journal of biological chemistry.

[5]  J. Hoak,et al.  Binding of human thrombin to cultured human endothelial cells. , 1979, The Journal of biological chemistry.

[6]  R. Huseby,et al.  A fluorescent substrate assay for plasminogen. , 1978, Thrombosis research.

[7]  M. Bull,et al.  Corticosteroid Treatment of Cutaneous Hemangiomas : How Effective? , 1978, Clinical pediatrics.

[8]  R. Huseby,et al.  Fluorescent substrate assay for antithrombin III. , 1978, Thrombosis research.

[9]  D. Loskutoff,et al.  Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[10]  E. Fonkalsrud,et al.  Prednisone therapy in the management of large hemangiomas in infants and children. , 1972, Surgery.

[11]  J. Hoak,et al.  Hemangioma with thrombocytopenia and microangiopathic anemia (Kasabach-Merritt syndrome): an animal model. , 1971, The Journal of laboratory and clinical medicine.

[12]  W. Moloney,et al.  Kasabach — Merritt syndrome: coagulo — analytical observations , 1971, The American journal of the medical sciences.

[13]  S. Inceman,et al.  Chronic defibrination syndrome due to a giant hemangioma associated with microangiopathic hemolytic anemia. , 1969, The American journal of medicine.

[14]  W. Shim.  Hemangiomas of infancy complicated by thrombocytopenia. , 1968, American journal of surgery.

[15]  F. Breen,et al.  Ethanol gelation: a rapid screening test for intravascular coagulation. , 1968, Annals of internal medicine.

[16]  R. Hillman,et al.  Clotting-fibrinolysis in a cavernous hemangioma. , 1967, American journal of diseases of children.

[17]  H. E. Brizel,et al.  Giant hemangioma with thrombocytopenia. Radioisotopic demonstration of platelet sequestration. , 1965, Blood.

[18]  R. Gage,et al.  CONGENITAL DEFICIENCY OF FACTOR VII (HYPOCONVERTINEMIA). CRITICAL REVIEW OF LITERATURE AND REPORT OF THREE CASES, WITH EXTENSIVE PEDIGREE STUDY AND EFFECT OF TRANSFUSIONS. , 1964, The American journal of medicine.

[19]  K. Merritt,et al.  CAPILLARY HEMANGIOMA WITH EXTENSIVE PURPURA: REPORT OF A CASE , 1940 .

[20]  G. Race,et al.  Fibrin stabilizing factor (factor XIII) , 1968 .